GSK's ovarian cancer treatment meets main goal in late-stage study

GSK's ovarian cancer treatment meets main goal in late-stage study

GlaxoSmithKline said on Monday a late-stage study testing Zejula as a maintenance therapy in patients with first-line ovarian cancer showed positive headline results.

The GSK logo is seen on top of GSK Asia House in Singapore
The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

REUTERS: GlaxoSmithKline said on Monday a late-stage study testing Zejula as a maintenance therapy in patients with first-line ovarian cancer showed positive headline results.

GSK agreed to buy U.S. cancer specialist Tesaro for US$5.1 billion in December, giving it a marketed product for ovarian cancer, Zejula, which belongs to a promising class of medicines.

The drugmaker said the study met its primary endpoint of a statistically significant improvement in progression free survival for women regardless of their biomarker status.

(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Arun Koyyur)

Source: Reuters

Bookmark